Plan B
This article was originally published in The Tan Sheet
Executive Summary
Label comprehension study analysis expected by early September, after which actual use study will begin in preparation for switch NDA, Women's Capital Corp. says Aug. 1. Firm also will gather post-marketing surveillance data on nonprescription emergency contraceptive use in Europe and British Columbia along with data from U.S. pilot programs. A behavioral study on EC use underway by UC-San Francisco researchers, who began recruitment in July (1"The Tan Sheet" Jan 1, p. 12). Label comp study expected to end in late 2001, with switch application planned for early summer 2002
You may also be interested in...
Rx-To-OTC Consumer Purchase Trends To Be Tracked By ACNielsen
ACNielsen's U.S. Homescan Rx/OTC Consumer Panel will help the pharmaceutical industry monitor consumers' purchasing trends with regard to new switch drugs, the market research firm contends
EC Nonprescription Access In 40 California Pharmacies Expected By 2003
A pilot program enabling pharmacists to dispense emergency contraceptives without a prescription in San Francisco Bay- and Los Angeles-area pharmacies should expand to 30 to 40 locations within three years, according to the nonprofit Public Health Institute.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC